Abstract: The present invention relates to: a pharmaceutical composition containing lysophosphatidylcholine or analogs thereof and antibiotics as active ingredients for boosting immunity or the treatment of bacterial infections; a method for boosting immunity or the treatment of bacterial infections, which comprises a step for administering the composition; and a kit containing the composition for boosting immunity or the treatment of bacterial infections.

Abstract: The present invention relates to a micro-sized bubble generator. A micro-sized bubble generator using a highly-dissoved solution based on a rotating unit according to an exemplary embodiment of the present includes: a rotating unit receiving a mixture of water and gas and discharging a solution while making the water and gas collide with each other and rotating the same; a dissolving tank storing the solution discharged from the rotating unit; and a nozzle unit receiving the solution and generating micro-sized bubbles in the water. Accordingly, a massive amount of micro-sized bubbles less than 100 nm in size can be generated.

Abstract: The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingophosphorylcholine) or derivatives thereof to the subject. The agonist ligands for G2A receptor according to the present invention and pharmaceutical- or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.

Abstract: A composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative of formula (I), decursinol, a pharmaceutically acceptable salt thereof or an extract of a plant of genus Angelicae containing same, wherein, R1 is H or CH3, R2 is —CH?CHCOOH or formula (a).

Abstract: The present invention relates to novel therapeutical use of agonist ligands specific to G2A receptor. More particularly, the present invention relates to methods for treating a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, or with microbial infection, in a subject, comprising administering LPC (lysophosphatidylcholine), SPC(sphingophosphorylcholine) or derivatives thereof to the subject. The agonist ligands for G2A receptor according hours after CLP according to the present invention and pharmaceutical or therapeutical composition comprising said ligands can be used effectively in treatment of a disease or disorder associated with neutrophil accumulation and hyperactivity and/or excessive release of IL-8, specifically inflammatory diseases and diseases associated with ischemia-reperfusion injury as well as microbial infection.

Abstract: A composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative of formula (I), decursinol, a pharmaceutically acceptable salt thereof or an extract of a plant of genus Angelicae containing same, wherein, R1 is H or CH3, R2 is —CH?CHCOOH or formula (a).

Abstract: Provided is a pharmaceutical composition which can effectively prevent and treat sepsis and stroke. The composition comprises lysophosphatidic acid or a pharmaceutically acceptable salt thereof as an effective ingredient.

Abstract: A composition for preventing or treating dementia comprising a hydroxycinnamic acid derivative of formula (I), decursinol, a pharmaceutically acceptable salt thereof or an extract of a plant of genus Angelicae containing same, wherein, R1 is H or CH3, R2 is —CH═CHCOOH or formula (a).